fbpx

Loading. Please wait.

PHONE: (973) 627-7888 OPENING HOURS: MONDAY-FRIDAY 9:00am-7:00pm, SATURDAY 9:00am-1:00pm

Acupuncture in Florham Park, NJ

Let's Talk!

Discover Long-Lasting Pain Relief with Acupuncture Treatments from Denville Medical

At Denville Medical, we aim to serve you with long-lasting quality of life through personalized acupuncture treatments in New Jersey. The path to a pain-free life begins with a friendly, informative appointment, where one of our doctors develops a customized treatment plan tailored to your body's needs. It starts with your first evaluation, where our experts learn about your medical history, diagnostic tests, current condition, and overall health goals. From there, we'll create your plan and help you hit your milestones until your quality of life is improved.

With treatments like needling, cupping, Gua Sha, and acupuncture in Florham Park, NJ, included in your scope of treatment, musculoskeletal relief is right around the corner.

If you're sick and tired of living with painful limitations, our doctors are here to help you live a normal life free of debilitating body issues. No surgery. No addictive medicine. Only comprehensive acupuncture treatments, crafted with health and happiness in mind.

Physical-therapy-phone-number 973-627-7888

Request a Consultation

Latest News in Florham Park, NJ

Aaron Rodgers wants Jets trade, but Packers ‘digging their heels in’ over compensation | Now what?

Aaron Rodgers wants to play for the Jets. He made that very clear Wednesday on “The Pat McAfee Show.”But he also admitted that there’s still work to be done before he ends up in Florham Park.And Rodgers, who has taken heavy criticism for dragging out this process, said that the real delay is because the two sides have not yet come to an agreement on what the Jets should give up for the 39-year-old future Hall of Fame quarterback. And Rodgers seemed to lay the blame at the feet of his soon-to-be former team....

Aaron Rodgers wants to play for the Jets. He made that very clear Wednesday on “The Pat McAfee Show.”

But he also admitted that there’s still work to be done before he ends up in Florham Park.

And Rodgers, who has taken heavy criticism for dragging out this process, said that the real delay is because the two sides have not yet come to an agreement on what the Jets should give up for the 39-year-old future Hall of Fame quarterback. And Rodgers seemed to lay the blame at the feet of his soon-to-be former team.

“I haven’t been holding anything up at this point,” Rodgers said. “It’s just the compensation that the Packers are trying to get for me, and kind of digging their heels in.”

Want to bet on the NFL?

See the best NJ Sports Betting sites

Rodgers said that he was 90 percent leaning toward retirement last month when he went into a four-day darkness retreat in Oregon. But when he emerged from the retreat, his mindset started to change -- in part, because the Packers who had previously left the door open to him, were now shopping him around according to some of his friends in the game.

He said he started thinking about a future in football beyond the Packers at that point, but still had questions about how his body would hold up. But when the Jets contingent visited him last week, Rodgers said that’s when he knew what he wanted to do in 2023.

“This was not a decision [made] here [Wednesday],” Rodgers said. “The decision was made in my mind, whether or not I was able to admit it at that point, really on that Tuesday [the Jets visited] that I wanted to play.

“And I think since Friday I made it clear that my intention was to play and my intention was to play for the New York Jets.”

So according to Rodgers at least, he didn’t leave the Packers or the Jets twisting in the wind over the weekend, even though the rest of the world was uncertain of his plans.

The first hints that the Packers and Jets were at odds over compensation came last Friday, when Packers president Mark Murphy said repeatedly in interview that the idea for the Packers was to find a situation that was a “win” for Rodgers and a win for the team he was leaving.

What happens next? Well, that’s complicated. The Packers have made it clear that they want to move on from Rodgers, and Rodgers has made it clear that he no longer wants to be in Green Bay after he says Packers management told him he was welcome back, but told others (including the world on Friday) that they wanted to move on.

Neither side has great leverage: the Packers are trying to trade a 39-year-old who just admitted he was 90 percent set on retiring a few weeks ago and probably need to clear his salary from their books to properly conduct business this offseason.

The Jets don’t have a backup plan at quarterback and need to make sure they land Rodgers and every day that goes on without a deal getting done, their desperate fan base will become more agitated and worried about the future.

At some point, someone will have to blink. But right now, it’s hard to tell if it will be sometime in the next week or something that could go all the way up to the NFL Draft at the end of April.

Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.

Florham Park Welcomes Mediterranean Eatery; Other Dining News

Restaurant Openings:Taim Mediterranean Kitchen, Florham ParkA favorite on the New York City scene, Taim is crossing the Hudson this week. Its customizable menu includes pitas, bowls, salads and other options while drawing from 18 different spices. On Sundays, Taim offers a special Crave Combo—featuring a signature pita and fries for $10—as well as a Family Meal, a Med...

Restaurant Openings:

Taim Mediterranean Kitchen, Florham Park

A favorite on the New York City scene, Taim is crossing the Hudson this week. Its customizable menu includes pitas, bowls, salads and other options while drawing from 18 different spices. On Sundays, Taim offers a special Crave Combo—featuring a signature pita and fries for $10—as well as a Family Meal, a Mediterranean feast that feeds four to six people. 176 Columbia Turnpike, Florham Park; 973-295-6966

Jarana, East Rutherford

Expected to open in late March in the American Dream Mall, this restaurant from international Peruvian chef Gaston Acurio offers ceviche, stir fry, stews, desserts and charcoal rotisserie. The bar in the middle of the restaurant offers tropical cocktails with house-made syrups; there’s also an extensive wine list. 1 American Dream Way, East Rutherford; 833-263-7326

New lunch menu at Nami Nori, Montclair

This new Japanese restaurant began offering lunch on February 7. Available Tuesday through Saturday, the menu includes tuna poke, scallop temaki, coconut shrimp temaki, kanpachi pineapple temaki, fries with tomato tonkatsu, and spicy tuna dip with crispy rice chips. 378 Bloomfield Avenue, Montclair; 201-292-1445

Rook Coffee, Wall Township

After a month-long renovation, this popular coffee chain has reopened its Wall location with a new layout. The shop first opened in 2014. 1924 NJ-35, Wall Township; 848-469-8340

86 & Vine, Norwood

An opening date has finally been set for this wine and cocktail parlor. 86 & Vine will begin welcoming guests during the last week of February. Choose from more than 300 spirits and 500 hand-picked wines, plus other cocktails and tapas-style bites. 519 Livingston Street, Norwood; 201-272-6767

No one knows New Jersey like we do. Sign up for one of our free newsletters here. Want a print magazine mailed to you? Purchase an issue from our online store.

Click here to leave a comment

Jets 2023 free agent tracker: Ex-Packer Allen Lazard agrees to four-year, $44 million deal

FLORHAM PARK, N.J. -- NFL free agency is off and running, and we're keeping track of every major signing, trade and release of the 2023 offseason, with analysis from our NFL Nation reporters and ...

FLORHAM PARK, N.J. -- NFL free agency is off and running, and we're keeping track of every major signing, trade and release of the 2023 offseason, with analysis from our NFL Nation reporters and grades from our experts. The first round of the 2023 NFL draft begins April 27 on ESPN.

The New York Jets enter free agency with two objectives: Improve their 25th-ranked offense and maintain the excellence they established last season on defense.

Once they resolve the quarterback situation, which figures to be their one big splurge, the Jets will be “judicious” (coach Robert Saleh’s word) in plugging holes on offense. Their primary need is center, but they have depth issues along the offensive line and at wide receiver. Look for them to sign multiple linemen. Their defense, which ranked fourth, could use help on the line (interior), safety and linebacker.

It seems like a lot, but the roster is in better shape than a year ago. They were among the leading free agent spenders in 2022 and they were tops in 2019, based on guaranteed money, per ESPN Stats & Information. Pressed against the salary cap, they won’t dole out as much money as last year. General manager Joe Douglas will pick his spots, looking for value but also knowing the franchise is in win-now mode.

Here's a breakdown of every 2023 NFL free agent signing by the New York Jets, and how each will impact the upcoming season:

Allen Lazard, wide receiver

Lazard agreed to terms on a four-year deal worth $44 million, a source told ESPN.

What it means: This will make Aaron Rodgers happy if he becomes the Jets' quarterback. Rodgers reportedly wanted Lazard, and general manager Joe Douglas delivered. Chances are, they would've made the move anyway because offensive coordinator Nathaniel Hackett, formerly the Packers' OC, is high on Lazard. This intensifies the speculation that Corey Davis could be released or traded. Talent-wise, it's probably a wash between Lazard and a healthy Davis, but Lazard, 27, is a year younger and more cap-friendly than the oft-injured Davis. They clear $10.5 million on the cap if they move on from Davis. The Jets' projected starting three: Lazard, Garrett Wilson and Elijah Moore (slot). They have former second-rounder Denzel Mims, too.

What's the risk: A reported $44 million over four years, including $22 million in guarantees, is not an insignificant amount of money in a depressed receiver market for a player who hasn't reached 800 yards in a season. But there are reasons to like this deal: At 6-foot-5, Lazard is a nice complement to Wilson and Moore and should be a nice target in the red zone, a problem area for the Jets. He's a fantastic blocker, reliable on third down (ranked ninth in catches for first downs, 18 in 2022) and he's coming off a career year as a receiver -- 60 catches, 788 yards and six touchdowns. Lazard may not have a high ceiling, but his floor is high enough to validate the deal.

Greg Zuerlein, kicker

The Jets agreed to terms with Zuerlein on a one-year, $2.6 million deal, including $1.8 million guaranteed.

What it means: Kicking stability! Re-signing Zuerlein means the Jets will have the same kicker in back-to-back seasons for the first time since 2016, when Nick Folk finished up a seven-year run with the team. Zuerlein, 35, was solid, if not stellar in his first season with the Jets. He made 81% of his field goals, below the NFL average (85%) in 2022. Highlights: A franchise-record 60-yarder and an 84% touchback rate, which ranked third in the league.

What's the risk: Zuerlein received a bump on last year's salary ($2 million), which ranked in the bottom-third among kickers. He provided consistency after a few years of musical kickers.

Quincy Williams, linebacker

The Jets agreed to terms with Williams on a three-year deal.

What it means: The Jets prioritized Williams and got him locked up before he hit the open market -- smart move. Williams, 26, is an ascending player coming off his rookie contract. Those are the kinds of players you want to keep. They now have two of their top three linebackers under contract, Williams and C.J. Mosley. The goal is to keep as many players as possible from last year's fourth-ranked defense. This is a good start.

What's the risk: The three-year, $18 million deal ranks 17th in the league among off-ball linebackers, based on average per year and it includes $9 million in guarantees. With incentives, it could max out at $21 million. This is a solid deal for both sides, with minimal risk for the Jets. It's a solid value for a starter who played 79% of the defensive snaps.

BASF strengthens diversity and inclusion efforts through sponsorship of the Women in Manufacturing Association

FLORHAM PARK, N. J., March 14, 2023 (GLOBE NEWSWIRE) -- BASF has announced the company will continue its more than $100,000 sponsorship of the Women in Manufacturing Association (WiM) in 2023. The sponsorship supports events, development programs and donations to five state chapters of the association with local BASF representatives in leadership roles.“WiM’s programming is a fantastic way for women who have chosen a career in the manufacturing industry to develop their leadership skills and network with other women,&rdquo...

FLORHAM PARK, N. J., March 14, 2023 (GLOBE NEWSWIRE) -- BASF has announced the company will continue its more than $100,000 sponsorship of the Women in Manufacturing Association (WiM) in 2023. The sponsorship supports events, development programs and donations to five state chapters of the association with local BASF representatives in leadership roles.

“WiM’s programming is a fantastic way for women who have chosen a career in the manufacturing industry to develop their leadership skills and network with other women,” said Cara Madzy, BASF’s Vice President of Coatings Americas and WiM Board Member. “At BASF, we have set a target to increase women in leadership to 30%, and this partnership complements our internal programming to help our future leaders get there.”

WiM is the only national and global trade association dedicated to providing year-round support to women who have chosen a career in the manufacturing industry. WiM presently powers year-round virtual learning, bi-annual virtual career fairs, executive networking group services, a job board, meetings and conferences annually, 32 local U.S. chapters and three formal professional development programs.

A portion of this year’s sponsorship includes donations to the Louisiana, Georgia, Texas, Michigan and Alabama chapters of WiM.

“We officially launched our chapter at the end of 2022 with 40 women representing 11 different companies,” said Kara Callicott, BASF Lab Technician and Co-Chair of the WiM Louisiana chapter. “This donation comes at the perfect time as we are planning ways to engage and inspire our members throughout 2023.”

This sponsorship is part of BASF’s strategy to attract, develop and retain top, diverse talent in its nearly 80 manufacturing facilities throughout North America. Visit www.basf.us/women to learn more.

About BASF

BASF Corporation, headquartered in Florham Park, New Jersey, is the North American affiliate of BASF SE, Ludwigshafen, Germany. BASF has approximately 16,000 employees in North America and had sales of $25.7 billion in 2022. For more information about BASF’s North American operations, visit www.basf.com/us.

At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 111,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €87.3 billion in 2022. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States. Further information at .

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufacture of fruquintinib outside China has closed.

With a strong preclinical and clinical profile, fruquintinib offers a potential new treatment option for patients with refractory metastatic colorectal cancer (“CRC”), supporting the shared goal of Takeda and HUTCHMED to improve the lives of those living with cancer worldwide. Takeda is now responsible for the development, commercialization and manufacture of fruquintinib in all included territories worldwide excluding mainland China, Hong Kong and Macau, where it is marketed by HUTCHMED.

Following the closing of the exclusive license agreement, HUTCHMED Limited will receive US$400 million shortly, and is eligible to receive up to US$730 million in additional potential payments relating to regulatory, development and commercial sales milestones, as well as royalties on net sales. Marketing authorization submissions in the U.S., Europe and Japan are planned to complete in 2023, with the rolling submission to the U.S. Food and Drug Administration (“FDA”) initiated in December 2022.

About Fruquintinib

Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity with the intention of minimizing off-target toxicities, improving tolerability and providing more consistent target coverage. Fruquintinib has been generally well tolerated in patients to date, and is being investigated in combinations with other anti-cancer therapies.

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/?immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: or follow us on .

For more information, visit .

Disclaimer:

This website publishes news articles that contain copyrighted material whose use has not been specifically authorized by the copyright owner. The non-commercial use of these news articles for the purposes of local news reporting constitutes "Fair Use" of the copyrighted materials as provided for in Section 107 of the US Copyright Law.

© Copyright 2022 Denville Medical.